# Pharmacy Translational Informatics: From Claims Data to Clinical Insights
## Multi-Method Analysis of Drug Patterns, Trajectories, and Outcomes

---

## 🎯 Presentation Overview

**Title**: "Translating Healthcare Claims Data into Actionable Clinical Insights: A Multi-Method Approach to Drug Pattern Analysis and Outcome Prediction"

**Target Audience**: Pharmacy Translational Informatics researchers, clinical informaticians, pharmacovigilance specialists

**Duration**: 45-60 minutes (with Q&A)

**Key Message**: Demonstrate how combining multiple analytical methods (FPGrowth, BupaR, CatBoost, DTW) transforms raw claims data into clinically actionable insights for drug safety and outcome prediction.

---

## 📋 Presentation Structure

### Slide 1: Title Slide
- **Title**: Translating Healthcare Claims Data into Actionable Clinical Insights
- **Subtitle**: Multi-Method Analysis of Drug Patterns, Trajectories, and Outcomes
- **Authors/Affiliation**
- **Date**

---

### Slide 2: The Translational Informatics Challenge
**Problem Statement**
- Healthcare claims data: Rich but complex
- Need: Translate patterns → Clinical insights → Actionable recommendations
- Challenge: Multiple analytical perspectives needed for comprehensive understanding

**Key Questions**:
1. Which drug patterns predict adverse outcomes?
2. How do patient trajectories differ between outcomes?
3. Can we identify causal relationships vs. associations?

**Visual**: Diagram showing Data → Analysis → Insights → Clinical Action

---

### Slide 3: Research Objectives
**Two Primary Research Questions**:

1. **ED_NON_OPIOID Cohort**
   - Does drug window influence target outcome?
   - Which drugs are involved?
   - Is there a temporal/ordering aspect?

2. **OPIOID_ED Cohort**
   - What CPT/ICD Codes and Drugs predict OPIOID_ED events?
   - Can we identify high-risk patient trajectories?

**Visual**: Two-panel diagram showing both cohorts

---

### Slide 4: Multi-Method Analytical Framework
**Our Approach**: Five Complementary Methods

```
1. FPGrowth → Pattern Discovery (What patterns exist?)
2. BupaR → Process Mining (How do sequences flow?)
3. CatBoost → Prediction (What predicts outcomes?)
4. DTW → Trajectory Clustering (Who follows similar paths?)
5. Enhanced CatBoost → Causality (What causes outcomes?)
```

**Key Insight**: Each method answers different questions; together they provide comprehensive understanding

**Visual**: Flow diagram showing method progression

---

### Slide 5: Data Infrastructure & Cohort Creation
**Cohort Design**:
- **Source**: APCD claims data (medical + pharmacy)
- **Cohorts**: OPIOID_ED (n=targets) vs. ED_NON_OPIOID (n=targets)
- **Controls**: 5:1 ratio, matched demographics
- **Temporal Windows**: 30-day lookback for ED_NON_OPIOID

**Key Features**:
- ✅ Balanced temporal windows (targets and controls)
- ✅ Statistical independence (no control reuse within cohorts)
- ✅ Complete event history (ICD, CPT, drugs)

**Visual**: Cohort creation pipeline diagram

---

### Slide 6: Method 1 - FPGrowth: Pattern Discovery
**Purpose**: Initial filtering and frequent pattern identification

**What it does**:
- Discovers frequent drug/ICD/CPT combinations
- Identifies association rules (Drug A → Drug B)
- Filters feature space before modeling

**Results**:
- **ED_NON_OPIOID**: Top 50 frequent drug patterns in 30-day window
- **OPIOID_ED**: Top 100 ICD patterns, Top 100 CPT patterns

**Clinical Value**: Identifies which drugs/codes are most commonly associated with outcomes

**Visual**: 
- Network diagram of frequent drug associations
- Top 10 frequent patterns table

---

### Slide 7: Method 2 - BupaR: Process Flow Analysis
**Purpose**: Understand temporal sequences and ordering

**What it does**:
- Analyzes drug/ICD/CPT sequences leading to outcomes
- Creates process flow diagrams
- Identifies common pathways (Drug A → Drug B → ED Visit)

**Results**:
- **ED_NON_OPIOID**: Drug sequence patterns in 30-day window
- **OPIOID_ED**: ICD → CPT → Drug → OPIOID_ED pathways

**Clinical Value**: Reveals temporal ordering and sequence patterns

**Visual**:
- Process flow diagram (Sankey plot)
- Sequence frequency analysis
- Example: "Most common drug sequence leading to ED visit"

---

### Slide 8: Method 3 - CatBoost: Predictive Modeling
**Purpose**: Feature importance and outcome prediction

**What it does**:
- Trains gradient boosting models
- Ranks features by importance
- Predicts outcomes from drug/ICD/CPT patterns

**Results**:
- **ED_NON_OPIOID**: Drug feature importance rankings
- **OPIOID_ED**: ICD/CPT/drug importance rankings
- Model performance metrics (AUC, precision, recall)

**Clinical Value**: Identifies most predictive features for risk stratification

**Visual**:
- Feature importance bar chart (top 20 features)
- ROC curve
- Confusion matrix

---

### Slide 9: Method 4 - DTW: Patient Trajectory Clustering
**Purpose**: Identify similar patient journeys

**What it does**:
- Creates patient trajectories from temporal sequences
- Clusters patients with similar patterns (DTW similarity)
- Identifies trajectory archetypes

**Results**:
- **ED_NON_OPIOID**: 5 drug trajectory clusters
- **OPIOID_ED**: 6 ICD clusters, 6 CPT clusters
- Archetype trajectories per cluster

**Clinical Value**: Enables personalized medicine approaches and risk stratification

**Visual**:
- Trajectory cluster visualization
- Archetype trajectories (representative patterns)
- Cluster characteristics table

---

### Slide 10: Method 5 - Enhanced CatBoost: Causality & Attribution
**Purpose**: Formal feature attribution and causal inference

**What it does**:
- Combines all previous analysis outputs as features
- Uses SHAP/LIME for feature attribution
- Assesses causal relationships

**Results**:
- Feature attribution scores (SHAP values)
- Causal effect estimates
- Enhanced predictive models

**Clinical Value**: Distinguishes causal relationships from associations

**Visual**:
- SHAP summary plot
- Feature attribution waterfall plot
- Causal effect estimates table

---

### Slide 11: Research Question 1 Results: ED_NON_OPIOID
**Question**: Does drug window influence target outcome and which drugs are involved?

**Key Findings**:

1. **FPGrowth**: Identified 50+ frequent drug patterns in 30-day window
   - Top drugs: [Drug A, Drug B, Drug C...]
   - Support: X%, Confidence: Y%

2. **BupaR**: Temporal ordering patterns identified
   - Common sequence: Drug A (day 30) → Drug B (day 15) → ED Visit (day 0)
   - Sequence frequency: Z%

3. **CatBoost**: Drug window significantly influences outcome
   - Model AUC: 0.XX
   - Top predictive drugs: [Ranked list]

4. **DTW**: 5 distinct trajectory clusters identified
   - Cluster 1: High-risk trajectory (Drug X → Drug Y → ED)
   - Cluster 2: Moderate-risk trajectory
   - ...

5. **Enhanced CatBoost**: Causal attribution
   - Drug window effect: [Effect size]
   - SHAP values: [Top attributions]

**Clinical Implications**:
- ✅ Drug window does influence outcomes
- ✅ Specific drugs identified as high-risk
- ✅ Temporal patterns provide early warning signals

**Visual**: Multi-panel figure showing all 5 method results

---

### Slide 12: Research Question 2 Results: OPIOID_ED
**Question**: What CPT/ICD Codes and Drugs predict OPIOID_ED events?

**Key Findings**:

1. **FPGrowth**: 
   - Top ICD codes: [List with frequencies]
   - Top CPT codes: [List with frequencies]
   - Top drugs: [List with frequencies]

2. **BupaR**: Predictive pathways identified
   - ICD → CPT → Drug → OPIOID_ED pathway
   - Sequence frequency analysis

3. **CatBoost**: Feature importance rankings
   - ICD codes: [Top 10]
   - CPT codes: [Top 10]
   - Drugs: [Top 10]
   - Model AUC: 0.XX

4. **DTW**: High-risk trajectory clusters
   - ICD trajectory clusters: [6 clusters]
   - CPT trajectory clusters: [6 clusters]
   - High-risk archetypes identified

5. **Enhanced CatBoost**: Causal attribution
   - ICD/CPT/drug causal effects
   - SHAP attributions

**Clinical Implications**:
- ✅ Predictive ICD/CPT codes identified
- ✅ High-risk patient trajectories identified
- ✅ Early intervention opportunities

**Visual**: Multi-panel figure showing all 5 method results

---

### Slide 13: Translational Informatics Insights
**From Data to Clinical Action**

**Pattern Discovery → Clinical Insights**:
- FPGrowth patterns → Identify commonly co-prescribed drugs
- BupaR sequences → Understand treatment pathways
- DTW clusters → Identify at-risk patient groups

**Prediction → Risk Stratification**:
- CatBoost models → Risk scores for individual patients
- Feature importance → Prioritize monitoring efforts
- Trajectory clusters → Personalized intervention strategies

**Causality → Evidence-Based Practice**:
- Enhanced CatBoost → Distinguish causal from associative
- SHAP values → Interpretable predictions
- Causal effects → Guide clinical decision-making

**Visual**: Three-panel diagram showing translation pathway

---

### Slide 14: Clinical Applications
**How This Translates to Practice**

1. **Early Warning Systems**
   - Use trajectory clusters to identify at-risk patients
   - Monitor patients following high-risk trajectories
   - Alert clinicians to potential adverse outcomes

2. **Drug Safety Monitoring**
   - Identify drug combinations associated with outcomes
   - Monitor temporal patterns (30-day window)
   - Flag high-risk drug sequences

3. **Personalized Medicine**
   - Match new patients to trajectory clusters
   - Predict outcomes based on patient history
   - Tailor interventions to trajectory type

4. **Clinical Decision Support**
   - Provide risk scores at point of care
   - Suggest alternative treatment pathways
   - Guide medication selection

**Visual**: Clinical workflow diagram

---

### Slide 15: Methodological Contributions
**Why Multi-Method Approach Matters**

**Complementary Strengths**:
- **FPGrowth**: Finds frequent patterns (what exists)
- **BupaR**: Analyzes sequences (how it flows)
- **CatBoost**: Predicts outcomes (what will happen)
- **DTW**: Clusters patients (who is similar)
- **Enhanced CatBoost**: Assesses causality (why it happens)

**Synergistic Value**:
- Each method answers different questions
- Combined insights more powerful than individual methods
- Comprehensive understanding of drug-outcome relationships

**Visual**: Venn diagram showing method overlap and unique contributions

---

### Slide 16: Limitations & Future Directions
**Current Limitations**:
- Claims data: Administrative, not clinical detail
- Temporal windows: 30-day window may miss longer-term effects
- Causality: Observational data limits causal inference
- Generalizability: Results specific to study population

**Future Directions**:
1. **Expand temporal windows**: Analyze longer-term patterns
2. **Multi-modal integration**: Combine claims + clinical notes + genomics
3. **Real-time monitoring**: Implement trajectory-based alerts
4. **Intervention studies**: Test trajectory-based interventions
5. **External validation**: Validate models in different populations

**Visual**: Roadmap diagram

---

### Slide 17: Key Takeaways
**Summary of Contributions**

1. **Methodological**: Multi-method framework for translational informatics
2. **Clinical**: Identified predictive patterns and trajectories
3. **Translational**: Bridge from data to clinical action
4. **Practical**: Actionable insights for clinical decision-making

**Impact**:
- ✅ Identified high-risk drug patterns
- ✅ Developed predictive models
- ✅ Created patient trajectory clusters
- ✅ Assessed causal relationships
- ✅ Enabled personalized risk stratification

**Visual**: Summary infographic

---

### Slide 18: Acknowledgments & Contact
- **Data Sources**: APCD claims data
- **Methods**: FPGrowth, BupaR, CatBoost, DTW
- **Infrastructure**: DuckDB, AWS S3
- **Contact Information**

---

## 🎨 Visual Recommendations

### Key Visuals to Include:

1. **Cohort Creation Pipeline** (Slide 5)
   - Flow diagram showing data → cohorts → analysis

2. **Multi-Method Framework** (Slide 4)
   - Circular or flow diagram showing 5 methods

3. **FPGrowth Network Diagram** (Slide 6)
   - Network graph of frequent drug associations

4. **BupaR Process Flow** (Slide 7)
   - Sankey diagram showing drug sequences

5. **CatBoost Feature Importance** (Slide 8)
   - Horizontal bar chart of top features

6. **DTW Trajectory Clusters** (Slide 9)
   - Timeline visualization of trajectory archetypes

7. **SHAP Summary Plot** (Slide 10)
   - Beeswarm plot of feature attributions

8. **Results Summary** (Slides 11-12)
   - Multi-panel figures combining all method results

9. **Translational Pathway** (Slide 13)
   - Three-stage diagram: Data → Analysis → Clinical Action

---

## 📊 Data to Highlight

### Quantitative Results:
- **Cohort Sizes**: Number of patients, events
- **FPGrowth**: Support/confidence metrics, number of patterns
- **CatBoost**: AUC, precision, recall, feature importance scores
- **DTW**: Silhouette scores, cluster sizes
- **SHAP**: Attribution values, causal effect sizes

### Qualitative Insights:
- **Pattern Interpretations**: What do frequent patterns mean clinically?
- **Trajectory Descriptions**: What characterizes each trajectory cluster?
- **Clinical Implications**: How can clinicians use these insights?

---

## 🎯 Presentation Delivery Tips

### For Each Method Section:
1. **Problem**: What question does this method answer?
2. **Approach**: How does the method work?
3. **Results**: What did we find?
4. **Clinical Value**: Why does this matter?

### Story Arc:
1. **Setup**: The challenge (Slide 2-3)
2. **Methods**: Our approach (Slide 4-10)
3. **Results**: What we found (Slide 11-12)
4. **Translation**: Clinical applications (Slide 13-14)
5. **Impact**: Takeaways (Slide 15-17)

### Engagement Strategies:
- **Interactive Elements**: Ask audience about their experience with similar challenges
- **Case Studies**: Present specific patient trajectory examples
- **Live Demo**: Show trajectory clustering visualization (if time permits)
- **Q&A Prompts**: "What other applications can you think of?"

---

## 📝 Supplementary Materials

### Handout Suggestions:
1. **Method Comparison Table**: Side-by-side comparison of all 5 methods
2. **Top Patterns List**: Top 20 drug/ICD/CPT patterns from FPGrowth
3. **Trajectory Archetypes**: Detailed descriptions of each trajectory cluster
4. **Feature Importance Rankings**: Complete rankings from CatBoost
5. **Code Repository**: Link to GitHub with analysis code

### Backup Slides:
- **Technical Details**: Deep dive into each method (if asked)
- **Additional Results**: Extended results tables
- **Validation Studies**: Cross-validation results
- **Sensitivity Analyses**: Robustness checks

---

## 🎓 Target Audience Considerations

### For Pharmacy Informatics Researchers:
- Emphasize methodological contributions
- Highlight multi-method integration
- Discuss computational efficiency

### For Clinical Pharmacists:
- Focus on clinical applications
- Emphasize actionable insights
- Provide practical examples

### For Healthcare Administrators:
- Highlight population health implications
- Discuss cost-effectiveness potential
- Show scalability

---

## ✅ Presentation Checklist

- [ ] Prepare all visualizations (network diagrams, process flows, feature importance charts)
- [ ] Create example patient trajectories for case studies
- [ ] Prepare backup slides for technical questions
- [ ] Practice timing (45-60 minutes)
- [ ] Prepare Q&A responses for common questions
- [ ] Test all visualizations on presentation screen
- [ ] Prepare handouts/materials
- [ ] Review key messages and takeaways

---

**Presentation Version**: 1.0  
**Last Updated**: January 2025  
**Based on**: Complete analysis workflow documentation and research findings

